We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer

Frank I. Scott, MD, MSCE1,2; Ronac Mamtani, MD, MSCE1,3; Colleen M. Brensinger, MS1,4; Kevin Haynes, PharmD, MSCE1; Zelma C. Chiesa-Fuxench, MD5; Jie Zhang, PhD6; Lang Chen, PhD7; Fenglong Xie, MS7; Huifeng Yun, PhD6; Mark T. Osterman, MD, MSCE2; Timothy Beukelman, MD, MSCE6; David J. Margolis, MD, PhD1,5; Jeffrey R. Curtis, MD, MS, MPH6,7; James D. Lewis, MD, MSCE1,2
[+] Author Affiliations
1Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia
2Division of Gastroenterology, University of Pennsylvania, Philadelphia.
3Abramson Cancer Center, University of Pennsylvania, Philadelphia
4Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia
5Department of Dermatology, University of Pennsylvania, Philadelphia
6Department of Epidemiology, University of Alabama at Birmingham
7Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham
JAMA Dermatol. 2016;152(2):164-172. doi:10.1001/jamadermatol.2015.3029.
Text Size: A A A
Published online

Importance  Immune dysfunction underlies the pathogenesis of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Immunosuppressive therapy is the standard of care for these diseases. Both immune dysfunction and therapy-related immunosuppression can inhibit cancer-related immune surveillance in this population. Drug-induced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous cell tumors. For patients with a history of NMSC, data are limited on the effect of these drugs on the risk of additional NMSCs.

Objective  To determine the relative hazard of a second NMSC in patients with RA or IBD who use methotrexate, anti–tumor necrosis factor (anti-TNF) therapy, or thiopurines after an initial NMSC.

Design, Setting, and Participants  In this retrospective cohort study, we studied 9460 individuals with RA or IBD enrolled in Medicare from January 1, 2006, through December 31, 2012.

Exposures  Exposure to methotrexate, thiopurines, anti-TNFs, sulfasalazine, hydroxychloroquine, abatacept, or rituximab after the incident NMSC surgery.

Main Outcomes and Measures  A second NMSC occurring 1 year or more after the incident NMSC using Cox proportional hazards regression models.

Results  Among 9460 individuals (6841 with RA and 2788 with IBD), the incidence rate of a second NMSC per 1000 person-years was 58.2 (95% CI, 54.5-62.1) and 58.9 (95% CI, 53.2-65.2) in patients with RA and IBD, respectively. Among patients with RA, methotrexate used in conjunction with other medications was associated with an increased risk of a second NMSC (hazard ratio [HR], 1.60; 95% CI, 1.08-2.37). Adjusted for other medications, the risk of NMSC increased with 1 year or more of methotrexate use (HR, 1.24; 95% CI, 1.04-1.48). Compared with methotrexate alone, the addition of anti-TNF drugs was significantly associated with risk of NMSC (HR, 1.49; 95% CI, 1.03-2.16). Abatacept and rituximab were not associated with increased NMSC risk. The nonsignificant HRs for 1 year or more of thiopurine and anti-TNF use for IBD were 1.49 (95% CI, 0.98-2.27) and 1.36 (95% CI, 0.76-2.44), respectively.

Conclusions and Relevance  Methotrexate use is associated with an increased risk of a second NMSC. Anti-TNF use may increase the risk of a second NMSC when used with methotrexate for RA. Further long-term studies are required before one can conclude that thiopurine and/or anti-TNF do not increase the risk of a second NMSC in patients with IBD.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Identification of Cohort Meeting Inclusion and Exclusion Criteria

Flowchart identifying individuals with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) who met the inclusion and exclusion criteria for study. Other dermatologic conditions consisted of xeroderma pigmentosa and albinism. Other immunosuppressive therapies included tacrolimus, cyclosporine, imiquimod, or fluorouracil. Cumulative exposure time is reported in median (interquartile range) and is measured among those who had received the drug. HIV indicates human immunodeficiency virus; NMSC, nonmelanoma skin cancer.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Clarifying Your Question

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Three Examples of Question Clarification